MetaCap

Nuvation Bio (NUVB) vs Tyra Biosciences (TYRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tyra Biosciences (TYRA) has outperformed Nuvation Bio (NUVB) over the past year, losing 4.7% versus a loss of 45.6%. Over five years, TYRA leads with a -15.7% price change compared with -53.5% for NUVB. Tyra Biosciences is the larger company by market cap ($1.39 billion vs $1.34 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NUVB-45.64%TYRA-4.73%
+94%+21%-53%
Nov 21, 20251 yearNov 20, 2026
NUVB-58.01%TYRA-16.17%
+73%-12%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NUVB versus TYRA key metrics
MetricNUVBTYRA
Share price$3.80$20.12
Market cap$1.34B$1.39B
1-day change-0.26%+1.98%
YTD return-57.59%-23.47%
1-year return-45.64%-4.73%
5-year return-53.49%-15.71%
EPS (TTM)$-0.39$-2.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$62.90M—
Revenue growth (YoY)+698.96%—
Net income (latest FY)$-204.63M$-119.95M
Operating margin-338.72%—
Net margin-325.31%—
52-week high$9.75$40.65
52-week low$3.71$18.25
Distance from 52-week high-61.03%-50.50%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+227.63%+135.83%
Average volume5.24M852.56K
Shares outstanding352.02M69.08M
Employees31087
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TYRA has outperformed NUVB by 40.9 percentage points over the past year.

About Nuvation Bio

NUVB stock →

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 310 employees

About Tyra Biosciences

TYRA stock →

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

NUVB vs TYRA FAQ

Which is bigger, Nuvation Bio or Tyra Biosciences?

Tyra Biosciences (TYRA) is larger, with a market capitalization of $1.39B compared with $1.34B for Nuvation Bio (NUVB).

Which stock has performed better over the past year, NUVB or TYRA?

TYRA returned -4.73% over the past 12 months, compared with -45.64% for NUVB (price return, excluding dividends). Past performance does not predict future results.

Are Nuvation Bio and Tyra Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons